prednisone has been researched along with Asthenia in 11 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Asthenia: Clinical sign or symptom manifested as debility, or lack or loss of strength and energy.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (54.55) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Shore, N | 1 |
| Mellado, B | 1 |
| Shah, S | 1 |
| Hauke, R | 1 |
| Costin, D | 1 |
| Adra, N | 1 |
| Cullberg, M | 1 |
| Teruel, CF | 1 |
| Morris, T | 1 |
| Puente, J | 1 |
| González-Del-Alba, A | 1 |
| Sala-Gonzalez, N | 1 |
| Méndez-Vidal, MJ | 1 |
| Pinto, A | 1 |
| Rodríguez, Á | 1 |
| Cuevas Sanz, JM | 1 |
| Muñoz Del Toro, JR | 1 |
| Useros Rodríguez, E | 1 |
| García García-Porrero, Á | 1 |
| Vázquez, S | 1 |
| Michaelson, MD | 1 |
| Oudard, S | 1 |
| Ou, YC | 1 |
| Sengeløv, L | 1 |
| Saad, F | 1 |
| Houede, N | 1 |
| Ostler, P | 1 |
| Stenzl, A | 1 |
| Daugaard, G | 1 |
| Jones, R | 1 |
| Laestadius, F | 1 |
| Ullèn, A | 1 |
| Bahl, A | 1 |
| Castellano, D | 1 |
| Gschwend, J | 1 |
| Maurina, T | 1 |
| Chow Maneval, E | 1 |
| Wang, SL | 1 |
| Lechuga, MJ | 1 |
| Paolini, J | 1 |
| Chen, I | 1 |
| Demiselle, J | 1 |
| Sayegh, J | 1 |
| Cousin, M | 1 |
| Olivier, A | 1 |
| Augusto, JF | 1 |
| COLTELLI, D | 1 |
| WOLF, SM | 1 |
| SCHOTLAND, DL | 1 |
| PHILLIPS, LL | 1 |
| Río, J | 1 |
| Nos, C | 1 |
| Bonaventura, I | 1 |
| Arroyo, R | 1 |
| Genis, D | 1 |
| Sureda, B | 1 |
| Ara, JR | 1 |
| Brieva, L | 1 |
| Martín, J | 1 |
| Saiz, A | 1 |
| Sánchez López, F | 1 |
| Prieto, JM | 1 |
| Roquer, J | 1 |
| Dorado, JF | 1 |
| Montalban, X | 1 |
| Marín, J | 1 |
| Lasa, R | 1 |
| Echeveste, A | 1 |
| Olcoz, M | 1 |
| Neira, F | 1 |
| Larraz, C | 1 |
| Larrañaga, MJ | 1 |
| Richier, JL | 1 |
| Guérin, D | 1 |
| Leblay, R | 1 |
| Pony, JC | 1 |
| Simon, GC | 1 |
| Métairie-Simon, P | 1 |
| Poleshko, DV | 1 |
| Novikov, PL | 1 |
| Astanov, AA | 1 |
| Mattison, NM | 1 |
| Feler, GI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Phase 3 Study Of Sunitinib Plus Prednisone Versus Prednisone In Patients With Progressive Metastatic Castration-Resistant Prostate Cancer After Failure Of A Docetaxel-Based Chemotherapy Regimen[NCT00676650] | Phase 3 | 873 participants (Actual) | Interventional | 2008-07-31 | Terminated (stopped due to Study A6181120 was prematurely discontinued due to futility on 27 September 2010. No new or unexpected safety issues were identified.) | ||
| A Trial of Prednisone and Acetaminophen Versus Acetaminophen Alone in Minimizing Flu-like Symptoms From Pegylated Interferon Beta-1a[NCT03424733] | Phase 4 | 50 participants (Anticipated) | Interventional | 2017-09-25 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
OS is the duration from randomization to death. For participants who were alive, overall survival was censored at the last contact. OS (in months) calculated as (date of death minus [-] date of randomization plus [+] 1) divided (/) 30.4. (NCT00676650)
Timeframe: Baseline up to 32 months
| Intervention | months (Median) |
|---|---|
| Sunitinib and Prednisone | 13.1 |
| Placebo and Prednisone | 11.8 |
OR defined as the percent (%) of participants with confirmed Complete Response (CR) (disappearance of all target lesions) or Partial Response (PR) (>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions) according to Response Evaluation Criteria in Solid Tumors (RECIST), relative to the full analysis population. Confirmed responses were those that persist on repeat imagining study >= 4 weeks after initial documentation of response. (NCT00676650)
Timeframe: Baseline, every 8 weeks up to 123 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Sunitinib and Prednisone | 6.1 |
| Placebo and Prednisone | 1.8 |
PFS is the period from randomization until disease progression or death on study. PFS is censored on the date of last tumor assessment documenting absence of progressive disease. PFS (weeks) calculated as (first event date - randomization date + 1)/7.02 (NCT00676650)
Timeframe: Baseline, every 8 weeks up to 123 weeks
| Intervention | weeks (Median) |
|---|---|
| Sunitinib and Prednisone | 24.1 |
| Placebo and Prednisone | 17.9 |
3 trials available for prednisone and Asthenia
| Article | Year |
|---|---|
A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Humans; Male; Phospha | 2023 |
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Di | 2014 |
Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Asthenia; Chills; Double-Blind Method; Drug Administ | 2004 |
8 other studies available for prednisone and Asthenia
| Article | Year |
|---|---|
Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).
Topics: Abiraterone Acetate; Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Anemia; Antineoplastic Ag | 2019 |
An Unusual Cause of Abdominal Pain: Lupus Enteritis.
Topics: Abdomen; Abdominal Pain; Acute Kidney Injury; Administration, Intravenous; Adult; Anti-Inflammatory | 2016 |
[New, rational approach in the oral treatment of convalescence & asthenia].
Topics: Abdominal Injuries; Administration, Oral; Asthenia; Convalescence; Cortisone; Female; Humans; Predni | 1957 |
INVOLVEMENT OF NERVOUS SYSTEM IN BEHCET'S SYNDROME.
Topics: Asthenia; Behcet Syndrome; Blood Cell Count; Blood Coagulation Tests; Cerebellar Diseases; Cerebrosp | 1965 |
[Hypereosinophilic syndrome: report of two cases, with acute blastic crisis in one (author's transl)].
Topics: Adult; Antineoplastic Agents; Asthenia; Eosinophilia; Female; Heart Diseases; Humans; Male; Nervous | 1982 |
[Therapeutic effect of alpha-tocopher- yl-quinone on muscular disorders of hyperthyroidism and of prolonged treatment by corticoids and antimitotics].
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Asthenia; Busulfan; Chlorambucil; Cobal | 1969 |
[2 cases of Crohn's disease].
Topics: Adrenocorticotropic Hormone; Adult; Asthenia; Colectomy; Crohn Disease; Dilatation; Humans; Intestin | 1969 |
[Immediate sequelae of meningococcic meningitis in children with modern methods of treatment].
Topics: Adolescent; Anti-Bacterial Agents; Asthenia; Child; Hemiplegia; Humans; Hydrocortisone; Hypertension | 1972 |